Logo_COVID19_NationalAwareness_Zambia.
Meeting category
Date(s)
16 Mar 2024
Location
Lusaka, Zambia
Meeting type
In-person
Virology Education

Zambian COVID-19 National Awareness Day 2024

Related Enduring Materials

Enduring Materials
Saturday, 16 March 2024
Session 1: COVID-19 Disease Burden and Clinical Spectrum -
Epidemiology of COVID-19, Including Long COVID - Key Lessons for Pandemic Preparedness
Nyambe Sinyange, BSc, MBChB, MSc
Zambia National Public Health institute (ZNPHI), Zambia
COVID-19 Clinical Spectrum, Risk factors, and Predictors of Poor Outcome
Lloyd Mulenga, BScHB, MBChB, MSc, MMed, PhD
Ministry of Health / University Teaching Hospital, Zambia
Long COVID: Definition & Clinical Spectrum
Gemma Lladós, MD
Hospital Germans Trias i Pujol, Spain
COVID-19 Diagnostics: Sorting out Respiratory illnesses
Mwaka Monze, BScHb, MBChB, MSc, PhD
University Teaching Hospital / University of Zambia, Zambia
Session 2: Prevention and Public Health Strategies -
Safety and Efficacy of COVID-19 Vaccines
Salim Abdool Karim, FRS
CAPRISA, South Africa
International and Local Guidelines for COVID-19 Vaccination
Roma Chilengi, BSc, MBChB, MSc
Zambia National Public Health Institute (ZNPHI), Zambia
Nonpharmaceutical Interventions – Do They Work?
Salim Abdool Karim, FRS
CAPRISA, South Africa
Session 3: COVID-19 Treatment -
Overview of COVID-19 Treatment Options
Lloyd Mulenga, BScHB, MBChB, MSc, MMed, PhD
Ministry of Health / University Teaching Hospital, Zambia
Treatment Guidelines & Clinical Management
Nyuma Mbewe, BSc, MBChB, MMed-ID
Zambia National Public Health Institute (ZNPHI), Zambia
Clinical Management of Long COVID
Gemma Lladós, MD
Hospital Germans Trias i Pujol, Spain
Opportunities for Virtual Clinics (Telemedicine)
Sombo Fwoloshi, BSc, MBChB, MMed, MSc
Ministry of Health / University Teaching Hospital, Zambia
Session 4: COVID-19 Management in Diverse Populations -
Pharmacology of SARS-CoV-2 Antiviral Drugs
David Burger, PharmD, PhD
Radboud UMC, The Netherlands
Real-life Management of DDIs in Complex Clinical Cases: Case 1 - Focus on TB
Chalomba Chitanika, MD, MMed
ICAP at Columbia University / Ministry of Health, Zambia
Real-life Management of DDIs in Complex Clinical Cases: Case 2 - Focus on Anticonvulsants
Sivile Suilanji, BSc, MBChB, MMed, MSc
University Teaching Hospital / Ministry of Health, Zambia
Panel Discussion: Implementation Opportunities & Challenges
Anita Bhebhe, MSc, BPharm
University Teaching Hospital, Zambia
Chalomba Chitanika, MD, MMed
ICAP at Columbia University / Ministry of Health, Zambia
Sivile Suilanji, BSc, MBChB, MMed, MSc
University Teaching Hospital / Ministry of Health, Zambia
Nyambe Sinyange, BSc, MBChB, MSc
Zambia National Public Health institute (ZNPHI), Zambia
Overview
About this program

The WHO declared the end of the COVID-19 pandemic as a public health emergency of international concern. With hospitalization and death rates in decline and a high population immunity, the disease became an established and ongoing health issue.

However, the risk of emerging variants remained, as well as the continuing need for medical education. This referred to knowledge of reliable and accurate diagnostic tools, staying up-to-date with recommendations and guidelines, and pharmacological properties of SARS-CoV-2 antiviral drugs, among other aspects. In addition, the epidemiology of long COVID showed worrisome rates, and an increased understanding of its management and outcomes was much needed.

Certain comorbidities have been associated with poor COVID-19 outcomes, including diabetes, obesity, hypertension, chronic obstructive pulmonary disease etc. Understanding risk factors and pharmacological properties, including drug-drug interactions, of SARS-CoV-2 antiviral drugs was instrumental to timely and comprehensive care of patients with a high risk of developing a severe disease form.

To this end, The Zambian COVID-19 National Awareness Day was aimed at raising awareness and facilitating education among healthcare professionals, public health experts, policymakers, and community representatives on disease burden, risk factors, and clinical management related to COVID-19. The program was tailored to the national healthcare system, accessible therapeutic options, and epidemiological patterns.

Program Director
Local Chair
General Information
Uniques Features
- Full Day Meeting
- Keynote Lectures
- Panel Discussion
- Audience Discussion
Who Should Attend?
- Primary care physicians
- Infectious disease clinicians, clinical virologists
- Pulmonologists, internal medicine doctors, cardiologists, neurologists,
- Immunologists, epidemiologists
- Pharmacists, pharmacologists, nurses
- Public health officials
- Community representatives
Learning Objectives
After participating in the proposed activities, the participants will be able to:

- Understand the COVID-19 epidemiology, pathology, and risk factors for poor outcomes
- Identify accessible diagnostic, prevention, and therapeutic options
- Comprehend pharmacological properties of antiviral drugs for COVID-19, and employ a drugdrug
interaction checker to assess potential harmful interactions
-Define main clinical considerations for COVID-19 management in diverse patient populations
(e.g. immunocompromised, renal impairment, pregnancy, or breastfeeding)
Practical Information 
Travel & Accommodation
The regisration for this conference does not include travel & accommodation expenses.
Entry Requirements
To determine whether you require a visa to enter Zambia, please visit the following website for information on entry requirements: https://www.zambiaimmigration.gov.zm/for-visitors/
Badges
All participants are requested to wear the badge at all times during the conference to ensure admission to the meeting.
Certificate of Attendance
A certificate of attendance will be sent to you after successfully completing the program and post-meeting survey.
Language
The official language of the conference/meeting/workshop is English.
Translation will not be provided.
Conference Materials
Conference materials can be obtained upon registration at the registration desk at the Conference Venue.
Disclaimer
This conference is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the conference.
Liability and Insurance
By registering for the conference participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official meeting sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided the speaker has given permission to do so.
Code of Conduct
All attendees, speakers, co-organizers, partners, endorsers, suppliers, volunteers, and employees at any of our programs are expected to observe our Code of Conduct. We cannot tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. All participants of VE and AME-organized programs are expected to treat others with dignity and respect at all times.

Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
DDI Checker

COVID-19 Drug-Drug Interaction Checker

Understanding drug-drug interactions (DDI) of SARS-CoV-2 antivirals is instrumental to the timely and comprehensive care of COVID-19 patients with co-existing medical conditions.

Based on the Zambian national formulary, this digital DDI checker will allow you to easily assess potentially harmful interactions and optimise care for your COVID-19 patients.

Additional Resources
Recommendations for the Public

On the link below you can find the WHO advice about measures to protect yourself and prevent the spreading of COVID-19. The guidelines span diverse topics from personal preventive measures, and safe environments, to recommended behaviour in case of symptoms onset.

WHO Advice for the Public

Additional national educational resources for long COVID are available on the links below. The program is accredited and supported by the Zambian Ministry of Health. It is aimed at healthcare providers involved in the clinical care of people living with long COVID and their families seeking information and support.

Pandemic Aftermath ECHO - Long COVID Series
 
Southern Africa Regional ECHO
Endorsers
Endorsers
Zambian COVID-19 National Awareness Day 2024 is endorsed by the following societies and organizations:
Become an Endorser
If you would like your organization to endorse or become a media partner of the Zambian COVID-19 National Awareness Day 2024, please contact Ms. Hana Agustine at Hana.Agustine@amededu.com.
Language